Lactobacillus gasseri SF1183 belongs to a subpopulation of bacteria tightly associated to the human ileal epithelium. Cells of SF1183 survive and grow in simulated intestinal and gastric conditions, have a strong antimicrobial activity against Gram-positives and Gram-negatives and secrete molecule(s) sensed by human intestinal cells. We report that the oral administration of SF1183 cells had a protective effect in a murine model of DSS (Dextran-Sulfate-Sodium)-induced colitis. The analysis of the intestinal microbial composition indicated that several bacterial genera were differently represented in the intestine of DSS-treated animals. An overall similar alteration was observed in the microbiota of DSS-treated animals that received SF1183, suggesting that the beneficial role of the probiotic was not played through a reshuffling of the intestinal flora. Based on our in vivo data we propose the SF1183 strain of L. gasseri as a new anti-inflammatory probiotic, potentially useful as a therapeutic agent for the treatment of IBDs.

盖氏乳杆菌SF1183属于与人类回肠上皮紧密相关的细菌亚群。SF1183细胞可以在模拟的肠道和胃部条件下存活并生长，对革兰氏阳性和革兰氏阴性菌具有很强的抗菌活性，并能分泌人肠道细胞所感知的分子。我们报告说，SF1183细胞的口服给药在DSS（右旋糖酐-硫酸盐-钠）诱导的结肠炎的小鼠模型中具有保护作用。肠道微生物组成的分析表明，DSS处理的动物的肠道中有几个细菌属具有不同的代表。在接受SF1183的经DSS处理的动物的微生物群中观察到总体相似的变化，这表明益生菌的有益作用并未通过肠道菌群的改组而发挥。根据我们的在体内数据中，我们提出了加氏乳杆菌SF1183菌株作为一种新型的抗炎益生菌，潜在地可用作治疗IBD的治疗剂。